ALTAltimmune Inc
ALT
Altimmune Inc39,562
Mkt Cap
$548.84MVolume
2.12M52W High
$10.8852W Low
$2.90PE Ratio
-4.92ALT Fundamentals
Price
$5.22Prev Close
$5.17Open
$5.2150D MA
$4.12Beta
1.38Avg. Volume
2.74MEPS (Annual)
-$1.34P/B
2.71Rev/Employee
$338.98Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT
Intech Investment Management LLC lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 102.9% during the second quarter, according to the company in its most recent Form 13F...
MarketBeat·17h ago
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat...
MarketBeat·3d ago
Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT)
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw some unusual options trading on Monday. Investors bought 11,978 call options on the company. This is an increase of 103% compared to the typical...
MarketBeat·5d ago
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·6d ago
FY2025 EPS Estimates for Altimmune Boosted by HC Wainwright
Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Altimmune in a research note issued to investors on Tuesday...
MarketBeat·16d ago
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS
Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29...
MarketBeat·22d ago
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT Altimmune, Inc. Securities Fraud Class Action Lawsuit...
PR Newswire·4mo ago
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Zacks·4mo ago
Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position
Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.